Early detection of ‘bubble boy disease' helps save lives of newborns
Mannat Singh was only six days old when he was diagnosed with Severe Combined Immunodeficiency (SCID). ST PHOTO: NG SOR LUAN
Medical Mysteries Early detection of 'bubble boy disease' helps save lives of newborns Medical Mysteries is a series that spotlights rare diseases or unusual conditions.
SINGAPORE – Mannat Singh was only six days old when he was diagnosed with Severe Combined Immunodeficiency (SCID).
This meant that he was born without a functioning immune system, making him highly vulnerable to even the common flu. Without treatment, Mannat would not have made it past his first birthday.
His mother Harminder Kaur, 39, a nurse, recalled the guilt and fear she felt 'because I made him this way'.
SCID is a rare life-threatening genetic disorder that affects one in 50,000 babies worldwide, with one new case born in Singapore every two years.
'It did not help our state of mind when his odds were stacked against him,' said her husband Harminder Singh, 39, an IT consultant.
It is also known as the 'bubble boy disease' after David Vetter, an American boy with the disease who captured the world's attention for living all his life in a sterile plastic enclosure – his 'bubble'.
At the time of his birth in 1971, a bone marrow transplant from an exact matched donor was the only cure for SCID, but there was no match available in David's family.
In 1984, four months after receiving a bone marrow transfusion via a new technique, the 12-year-old died from lymphoma, a cancer later traced to a dormant Epstein-Barr virus in the donor bone marrow.
As for baby Mannat, he had Artemis SCID, a rare form of recessive radiosensitive SCID, which meant he could not be treated with radiation or have certain scans done.
Mannat Singh was born without a functioning immune system, making him highly vulnerable to even the common flu.
ST PHOTO: NG SOR LUAN
Memories of what the couple went through with their younger son brought back tears to Mr Singh, who said: 'We were prepared to do whatever we could to give Mannat the best chance at life. We took a step at a time, discussing putting him on chemotherapy and deferring to the experts.'
Fortunately for Mannat, his condition was picked up at the KK Women's and Children's Hospital (KKH) through the National Expanded Newborn Screening (Nens) programme.
The programme, which started in 2006 with the aim of screening all babies born in Singapore for metabolic and heritable diseases, was expanded in 2019 to include five other treatable serious childhood-onset conditions such as SCID and cystic fibrosis.
In 2024, all newborns at KKH were screened under Nens, while the national screening rate in Singapore is 96 per cent. This involves pricking the baby's heels to collect a blood sample between 24 and 72 hours after birth.
Screening for SCID involves checking the baby's bloody for DNA fragments called T-cell receptor excision circles (Trecs), which show that the immune system is making T-cells properly, said geneticist from KKH Ting Teck Wah.
The test does not confirm an SCID diagnosis, but abnormalities such as low or absent Trecs signals that the baby needs to go through more testing, he said.
After screening almost 178,000 babies since 2019, Nens has picked up two babies positive for SCID, Dr Ting added.
Dr Bianca Chan, a consultant with the rheumatology and immunology services at KKH, said the only real curative treatment for SCID is a bone marrow transplant from a healthy donor. Stem cells from the bone marrow from a health donor can develop into infection-fighting T-cells, helping babies with SCID build a functioning immune system.
'The highest success is when it is performed within the first three to four months of life, before the baby develops significant infections. This makes SCID screening at birth crucial for early diagnosis to actively prevent infection,' she said.
Dr Chan added that if the baby has an active infection before the transplant, its survival rate even with transplant is only 50 per cent 'because it becomes very, very difficult to have a successful transplant'.
Mannat Singh and parents Harminder Kaur and Harminder Singh, with KKH doctors (back row, from left) Dr Michaela Seng, Dr Ting Teck Wah and Dr Bianca Chan.
ST PHOTO: NG SOR LUAN
Dr Michaela Seng, a senior consultant with the haematology and oncology service at the hospital, said a programme is immediately put in place to protect the child from infections before doctors prepare for donor selection.
'We meet the parent to explain the implications of the diagnosis and tell them they are typically appropriately suitable as potential donors. We also go through the process of harvesting and processing the donor stem cells, how the lab then receives these stem cells ... and prepare small bags of what we call memory T-cells that help fight infection,' she said.
'During this time, the baby, is admitted to the transplant unit and undergoes complete isolation. For seven days, he is given conditioning therapy, which is chemotherapy that is tailored to the size and the weight of the baby to allow us to clear unnecessary cells that would prevent successful engraftment of the donor stem cells. The donor cells are then infused, and we wait for the transplant to take effect,' she added.
Mannat became the first newborn in Singapore to have his SCID diagnosed at birth and the first to receive a stem cell transplant – from his mother's bone marrow – before the symptoms emerge.
Today, at 19 months, Mannat is healthy and asserting himself with his parents and older brother Birakaal, aged four.
'I feel now that life has returned to normal and we have put the past behind us. We are now looking forward to having the boys grow up healthy and happy,' Ms Kaur said.
Join ST's WhatsApp Channel and get the latest news and must-reads.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
7 hours ago
- Business Times
Asia healthcare assets risk overvaluation as private investors scoop them up
[SINGAPORE] As private equity (PE) investors pour money into Asian healthcare, some observers are concerned that this sector could soon overheat. Some recent deals this year include KKR's US$400 million purchase of a 54 per cent stake in India's Healthcare Global Enterprises in February. In Singapore, another American PE firm TPG took Catalist-listed nursing operator Econ Healthcare private in a deal worth nearly S$88 million. When the proposed transaction was announced in February, the offer price represented a 20 per cent premium to Econ's last traded share price on Jan 14. 'We are not the only ones to see the opportunity of healthcare in Asia, and, as a consequence, valuations can be high,' Abrar Mir, co-founder and managing partner of healthcare-focused PE firm Quadria Capital, told The Business Times. Other factors driving investors to the healthcare sector – perceived as defensive, and so able to withstand the ups and downs of economic cycles – is the ongoing macroeconomic uncertainty and volatility in global financial markets. This is particularly so in Asia, where investors have been diversifying away from China in the last few years, to avoid being caught in the cross hairs of the nation's tensions with the United States. As PE firms and their investors focus on acquiring companies independent of China, more deals have been transacted in Japan, South Korea and India, where the demand for healthcare and related services is strong and largely unaffected by tariffs. 'Japan has always been a stable healthcare market, and particularly because of (its) demographics and medical needs,' said David Braga Malta, thematic health principal at Pictet Alternative Advisors, to BT. 'We saw some of the mid-sized Japanese pharma companies being very acquisitive in the recent months and years... And of course, we saw the boom in the IPO (initial public offering) markets in India last year.' BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up Asia's appeal even drew European PE investors to buy South Korean assets for the first time in 2024, he added. Last September, France's Archimed spent US$742 million buying Jeisys Medical, a South Korean developer of aesthetic medicine devices. Like shopping in Louis Vuitton 'One of the key things that I always say to my investors is that... investing in healthcare in Asia is like shopping in Louis Vuitton. So, as an investor, we have to navigate that, be careful not to overpay,' said Quadria Capital's Mir. According to a Bain & Co report, global PE deal value in the sector surged last year to an estimated US$115 billion – the second highest on record. Bain added that PE firms continue to invest in healthcare in the Asia-Pacific, where deal values have been steadily rising since 2016. Industry participants named India as the country attracting the most number of healthcare PE investors. An ageing population, rising incidence of chronic disease and growing awareness of preventive care, combined with the opening up of its insurance market to foreign investment, are making India stand out. Bain estimated that the country made up 26 per cent of the 62 deals transacted in the Asia-Pacific last year. PwC said its health industries practice in India hit a double-digit compound annual growth rate in the past few years as well. But Ling Tok Hong, deals and private equity leader at PwC, cautioned that 'this continued focus on the India market could make it more susceptible to overvaluation if investors are not cautious'. South-east Asia's healthcare sector is also attracting PE investors, leading to 'unprecedented valuations' of Ebitda multiples in their 20s, noted Ling. He was referring to earnings before interest, taxes, depreciation and amortisation. Room for growth; returns still strong Despite the rising valuations in Asia's healthcare sector, market participants point out that there is still room for growth, a key factor backing the higher valuations in the first place. The sector offers attractive long-term growth prospects as the supply of quality healthcare assets in the region is not growing quickly enough to meet demand. In markets such as South-east Asia, 'the number of large, institutionally ready platforms is still limited. This scarcity has helped sustain high entry multiples in recent years', said Alex Boulton, partner and Asia-Pacific lead for healthcare and life sciences private equity at Bain. He pointed out that South-east Asia's healthcare sector relies heavily on private players. For instance, the private sector accounts for roughly half of all hospital beds in Indonesia and the Philippines. 'That structural dynamic creates an enduring role for private capital in expanding and upgrading healthcare infrastructure.' Market participants emphasise that Asian healthcare is not in bubble territory. Boulton pointed out that even with rising valuations, healthcare PE in Asia is still delivering strong returns. Bain's analysis shows that from 2018 to 2023, the median multiple on invested capital (MOIC) for exited healthcare deals in the region was approximately 2.6 – meaning that a US$1 million investment generated a return of US$2.6 million. This compares with the global median MOIC of around two. 'That speaks to the sector's ability to compound value through growth and operational improvement, even in a more expensive entry environment,' noted Boulton. That said, while returns are likely to remain strong in the future, the median MOIC may not be sustained at these levels, he added. Thus, market players said, investors will need to have a clear plan to create meaningful impact and value over the life of their investments.
Straits Times
10 hours ago
- Straits Times
Early detection of ‘bubble boy disease' helps save lives of newborns
Mannat Singh was only six days old when he was diagnosed with Severe Combined Immunodeficiency (SCID). ST PHOTO: NG SOR LUAN Medical Mysteries Early detection of 'bubble boy disease' helps save lives of newborns Medical Mysteries is a series that spotlights rare diseases or unusual conditions. SINGAPORE – Mannat Singh was only six days old when he was diagnosed with Severe Combined Immunodeficiency (SCID). This meant that he was born without a functioning immune system, making him highly vulnerable to even the common flu. Without treatment, Mannat would not have made it past his first birthday. His mother Harminder Kaur, 39, a nurse, recalled the guilt and fear she felt 'because I made him this way'. SCID is a rare life-threatening genetic disorder that affects one in 50,000 babies worldwide, with one new case born in Singapore every two years. 'It did not help our state of mind when his odds were stacked against him,' said her husband Harminder Singh, 39, an IT consultant. It is also known as the 'bubble boy disease' after David Vetter, an American boy with the disease who captured the world's attention for living all his life in a sterile plastic enclosure – his 'bubble'. At the time of his birth in 1971, a bone marrow transplant from an exact matched donor was the only cure for SCID, but there was no match available in David's family. In 1984, four months after receiving a bone marrow transfusion via a new technique, the 12-year-old died from lymphoma, a cancer later traced to a dormant Epstein-Barr virus in the donor bone marrow. As for baby Mannat, he had Artemis SCID, a rare form of recessive radiosensitive SCID, which meant he could not be treated with radiation or have certain scans done. Mannat Singh was born without a functioning immune system, making him highly vulnerable to even the common flu. ST PHOTO: NG SOR LUAN Memories of what the couple went through with their younger son brought back tears to Mr Singh, who said: 'We were prepared to do whatever we could to give Mannat the best chance at life. We took a step at a time, discussing putting him on chemotherapy and deferring to the experts.' Fortunately for Mannat, his condition was picked up at the KK Women's and Children's Hospital (KKH) through the National Expanded Newborn Screening (Nens) programme. The programme, which started in 2006 with the aim of screening all babies born in Singapore for metabolic and heritable diseases, was expanded in 2019 to include five other treatable serious childhood-onset conditions such as SCID and cystic fibrosis. In 2024, all newborns at KKH were screened under Nens, while the national screening rate in Singapore is 96 per cent. This involves pricking the baby's heels to collect a blood sample between 24 and 72 hours after birth. Screening for SCID involves checking the baby's bloody for DNA fragments called T-cell receptor excision circles (Trecs), which show that the immune system is making T-cells properly, said geneticist from KKH Ting Teck Wah. The test does not confirm an SCID diagnosis, but abnormalities such as low or absent Trecs signals that the baby needs to go through more testing, he said. After screening almost 178,000 babies since 2019, Nens has picked up two babies positive for SCID, Dr Ting added. Dr Bianca Chan, a consultant with the rheumatology and immunology services at KKH, said the only real curative treatment for SCID is a bone marrow transplant from a healthy donor. Stem cells from the bone marrow from a health donor can develop into infection-fighting T-cells, helping babies with SCID build a functioning immune system. 'The highest success is when it is performed within the first three to four months of life, before the baby develops significant infections. This makes SCID screening at birth crucial for early diagnosis to actively prevent infection,' she said. Dr Chan added that if the baby has an active infection before the transplant, its survival rate even with transplant is only 50 per cent 'because it becomes very, very difficult to have a successful transplant'. Mannat Singh and parents Harminder Kaur and Harminder Singh, with KKH doctors (back row, from left) Dr Michaela Seng, Dr Ting Teck Wah and Dr Bianca Chan. ST PHOTO: NG SOR LUAN Dr Michaela Seng, a senior consultant with the haematology and oncology service at the hospital, said a programme is immediately put in place to protect the child from infections before doctors prepare for donor selection. 'We meet the parent to explain the implications of the diagnosis and tell them they are typically appropriately suitable as potential donors. We also go through the process of harvesting and processing the donor stem cells, how the lab then receives these stem cells ... and prepare small bags of what we call memory T-cells that help fight infection,' she said. 'During this time, the baby, is admitted to the transplant unit and undergoes complete isolation. For seven days, he is given conditioning therapy, which is chemotherapy that is tailored to the size and the weight of the baby to allow us to clear unnecessary cells that would prevent successful engraftment of the donor stem cells. The donor cells are then infused, and we wait for the transplant to take effect,' she added. Mannat became the first newborn in Singapore to have his SCID diagnosed at birth and the first to receive a stem cell transplant – from his mother's bone marrow – before the symptoms emerge. Today, at 19 months, Mannat is healthy and asserting himself with his parents and older brother Birakaal, aged four. 'I feel now that life has returned to normal and we have put the past behind us. We are now looking forward to having the boys grow up healthy and happy,' Ms Kaur said. Join ST's WhatsApp Channel and get the latest news and must-reads.
Straits Times
3 days ago
- Straits Times
Volunteers knit bra inserts for breast cancer survivors to dress well, regain confidence
Minister for Digital Development and Information Josephine Teo launching Knitted Knockers@NHG, where volunteers can knit and distribute the bra inserts, on June 6. ST PHOTO: TARYN NG SINGAPORE - In her quest to find the right filling for her bra after undergoing mastectomy, breast cancer survivor Lyn Ee, 74, discovered Knitted Knockers, soft breast prostheses made from cotton yarn. 'They not only provide a gentler, softer alternative to the traditional breast prosthetics that can be hot and heavy, they also give back to breast cancer survivors their looks, confidence and peace of mind,' Ms Ee said. Today, 10 years after her discovery , the soft mounds of cotton yarn are being distributed free at all restructured hospitals in Singapore to women who have had mastectomy. Wanting to share her discovery of the prostheses with others here, Ms Ee in 2015 founded Knitted Knockers Singapore, t he local chapter of the American non-profit that has expanded internationally, gathering a group of volunteers to knit the bra inserts to give to breast cancer patients. Knitted Knockers@NHG (National Healthcare Group), where volunteers can knit and distribute the bra inserts, was launched on June 6 by Minister for Digital Development and Information Josephine Teo. Speaking at an event marking the 15th anniversary of the Tan Tock Seng Hospital (TTSH) Breast Clinic, Mrs Teo cited the initiative as an example of the good work the clinic has done. 'You want to provide the best clinical care and are equally keen to support the emotional well-being of your patients . The fact that you have put as priority helping patients regain a sense of normalcy and confidence – particularly for women who have had to go through mastectomies – is admirable ,' she said at the event. Minister for Digital Development and Information Josephine Teo (right) greeting breast cancer survivor Lyn Ee. ST PHOTO: TARYN NG Mrs Teo also shared the story of Ms Carmelita Calesagsag, her family's foreign domestic helper of 27 years who is a breast cancer survivor. The 61-year-old Filipina , fondly called Carmen by the Teos, has been working for the family for 27 years. Mrs Teo said: 'I remember vividly the day she was diagnosed. After she had reported a lump, Carmen had been sent by our family doctor to be properly tested. Parliament was in session when I received Carmen's phone call. I guessed it was bad news, because she would otherwise have waited till I got home . 'Over the next few weeks, I saw her struggle with fear and despair. Against the advice of some, we decided she should be treated in Singapore instead of being sent home. Now, 17 years later, we are glad we made that choice. Carmen is fully recovered. She watched all three of our children become working adults and remains very much a part of our family.' Ms Carmelita Calesagsag (right) has been working for Mrs Teo's family for 27 years. PHOTO: COURTESY OF JOSEPHINE TEO Breast cancer is the most prevalent cancer among women in Singapore, making up nearly 30 per cent of all cancers diagnosed among women here. The incidence here has more than tripled over the past 50 years, to 74 cases per 100,000 women now – one of the highest in Asia. The Breast Clinic has performed more than 6,100 breast cancer surgical operations since 2010 and over 450 in 2024 alone, the largest number within the NHG cluster last year . One of the clinic's latest innovations is endoscopic breast surgery that combines keyhole mastectomy with immediate breast reconstruction. The minimally invasive procedure is performed in the same setting by both a specially trained breast surgeon and a plastic surgeon. Cancerous tissue is removed from the affected breast, which is immediately reconstructed by the plastic surgeon using the patient's own skin, fat, and blood vessels. Since its introduction at the clinic in November 2024, three of its patients have undergone this advanced dual procedure. The first patient to undergo the procedure was polytechnic lecturer Kwa Sai Geok, 62, who was diagnosed with Stage 1 breast cancer during a routine mammogram in 2024. Polytechnic lecturer Kwa Sai Geok was the first patient to undergo endoscopic breast surgery at the Tan Tock Seng Hospital Breast Clinic. PHOTO: COURTESY OF KWA SAI GEOK Describing herself as 'a forward-looking person and always trying my best to shorten the time to pull myself back up', Madam Kwa said she opted for the keyhole mastectomy and reconstructive breast surgery to future-proof her health. 'I did not feel any pain during the four-day stay in hospital... and life was back to normal about four months after my right hand fully recovered with the help of the TTSH physiotherapist,' she said. Dr Ang Wei-Wen, a consultant from Breast Surgery Service at TTSH, said that not everyone is suitable for the minimal-scar endoscopic mastectomy and reconstructive surgery. 'This is due to various factors, such as the stage and type of cancer, the patient's overall health, and the location and size of the tumour,' he said. Dr Ang said the next step would be to use robotics for the procedure. 'It is the future of breast surgery and already a trend in South Korea. It has more dexterity than a human surgeon, leading to smaller incisions, reduced pain, and faster recovery,' he added. Join ST's WhatsApp Channel and get the latest news and must-reads.
